期刊文献+

卵巢癌临床治疗回顾及展望 被引量:9

Clinical Review and Outlook of Ovarian Cancer
下载PDF
导出
摘要 卵巢癌是女性生殖道恶性肿瘤中死亡率最高的恶性肿瘤,尽管大量的分子生物学领域研究的开展,为卵巢癌的未来治疗可能打开一片新的天地,但现在临床上依然是以手术治疗为主,化疗和放疗辅助治疗。本文通过回顾和结合现阶段最新的临床治疗指南,探讨卵巢癌的治疗方法,希望能对卵巢癌的手术预后的改善有所帮助。 The ovarian cancer is female genital tract malignant tumors in the highest mortality rates malignant tumor. Although a lot of research inthe field of molecular biology in the future for ovarian cancer therapy, now still clinical surgical treatment is given for priority, chemotherapy and radiation therapy is adjuvant. This paper based on the review and combined with present the latest clinical treatment guidelines for ovarian cancer treatment, givescommon discussion, in hopes of ovarian cancer surgery, to improve the prognosis.
作者 刘莹 张颖
出处 《中国医学创新》 CAS 2013年第12期153-154,共2页 Medical Innovation of China
关键词 卵巢癌 临床治疗 Ovarian cancer Clinical treatment
  • 相关文献

参考文献8

  • 1NCCN clinical practice guidelines in oncology, Ovarian Cancer,including fallopian tube tumor and primary peritoneal (*anrer[A].2011.
  • 2Munkarah A R, Hallurn A V, Morris M, el al. Prognostic signiHcanceof residual disease in patients with stage IV epithelial ovarian oancer[JJ-Gynecol Oncol, 1997, 64 ( 1 ) : 13-17.
  • 3Curtin J P, Malik R, Venkatraman E S, et al. Stage IV ovarian cancer:impart of surgi(;al debulkin^J]. Gynecol Oncol, 1997, 64 ( 1 ):9-12.
  • 4Colombo N, Guthrie D, Chiari S, et al. International CollaborativeOvarian Neoplasm trial 1 : a randomized trial of adjuvant chemotherapyin women with early stage ovarian can<*er[J j.Natl (lancer Insl, 2003,95 C 2 ) : L 25-132.
  • 5Chambers J T, Chambers S K, Voynick I M, et al. Neoadjuvantrhemolherapy in stage X ovarian carcinoma[J]. Gynecol Oncol, 1990,37 (3): 327-331.
  • 6Chan J K, Tian C, Fleming G F, et al. The potential benefit of 6 VS.3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a GynecologicOncology Group sludy[J]. Gynecol Oncol, 2010, 116 ( 3 ) : 301-306.
  • 7路伟,付玲娣,杨钧,钱涛.趋化因子CXCL12及其受体CXCR4在人脑星形细胞肿瘤中的表达及意义[J].脑与神经疾病杂志,2010,18(3):205-208. 被引量:3
  • 8Kajiyama H, Shihala K, Terauchi M, et al. Involvement of SDF-1 a /CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovariancarcinoma[J]. Int J Cancer, 2008, 122 ( 1 ) : 91-99.

二级参考文献8

  • 1Balkwill F.The significance of cancer cell expression of the chemokine receptor CXCR4.Semin Cancer Biol,2004,14:171- 179.
  • 2Yokoyama Y,Sato S,Futagami M,et al.Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma.Gynecol Oncol,2000,77:413-418.
  • 3Taichman RS,Cooper C,Keller ET,et al.Use of the stromal cell-derived factor-1/CXCR4 pathway in protstate cancer metastasis to bone.Caner Res,2002,62:1832-1837.
  • 4Zlotnik A,Yoshie O.Chemokines:a new classification system and their role in immunity.Immunity,2000,12:121- 127.
  • 5Horuk R.Chemokine receptors.Cytokine Growth Factor Rev,2001,12:313-335.
  • 6Redjal N,Chan JA,Segal RA,et al.CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.Clin Cancer Res,2006,12:6765- 6771.
  • 7Ehtesham M,Stevenson CB,Thompson RC.Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.Neurosurgery,2008,63:E820.
  • 8Feil C and Augustin HG.Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines.Biochem Biophys Res Commun,1998,247:38-45.

共引文献2

同被引文献103

  • 1李春颖,吴鸣,原劲阳.血小板及纤维蛋白原对卵巢癌患者病情进展的影响[J].中国医学科学院学报,2009,31(1):81-83. 被引量:7
  • 2林懿,林英城,林文照,王鸿彪,林穗玲,曾德,霍霞.纤维蛋白原水平在恶性肿瘤诊治中的临床意义[J].中国癌症杂志,2004,14(6):521-522. 被引量:9
  • 3刘秀峰,秦叔逵.洛铂的临床研究进展[J].临床肿瘤学杂志,2006,11(7):549-552. 被引量:53
  • 4蔡斌,张佳荣,谢毅,万小平.复发性卵巢癌的治疗选择——手术还是化疗[J].国外医学(妇产科学分册),2006,33(6):439-442. 被引量:4
  • 5连丽娟,林巧稚.妇科肿瘤学[M].第4版.北京:人民卫生出版社.2006:410-413,459-460.
  • 6连利娟,林巧稚.妇科肿瘤学[M].北京:人民卫生出版社,2006,405-406.
  • 7Roshan A, Start B.Ovarian cancer: stategies for overcoming resistance to chemotherapy[J].Nature Reviews Cancer Volume, 2003, 3 ( 1 ), 502-516.
  • 8Rajesh K, Lawrence D M.Muhidrug resistance ( MDR ) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[J]. European Journal of Pharmaceutical Sciences, 2000, 11 ( 4 ) : 265- 283.
  • 9Fecher L A, Amaravadi R K, Flaherty.The MAPK pathway in melanoma[J].Curr Opin Oncol, 2008, 20 (2), 183-189.
  • 10Ohta T, Ohmichi M, Hayasaka T, et al.Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in vivo ovarian cancer models[J].Endocrinology, 2006, 147 (14) : 1761- 1769.

引证文献9

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部